Effect of TNFi on ASAS20 and ASAS40 responses according to the CRP/MRI status at baseline in patients with nr-axSpA.
| MRI—AND CRP− | MRI+AND/OR CRP+ | MRI+AND CRP+ | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|
| Outcome Drug (study) | Time point (weeks) | N patients | RR (95% CI) | NNT | N patients | RR (95% CI) | NNT | N patients | RR (95% CI) | NNT |
| ASAS 20 | ||||||||||
| Etanercept (EMBARK25) | 12 | 26 | 3.82 (0.95 to 15.36) | 2.5 | – | – | – | 77 | 1.48 (0.97 to 2.27) | 4.7 |
| Adalimumab (ABILITY-127) | – | – | – | – | – | – | – | – | – | – |
| Golimumab (GO-AHEAD28) | 16 | 39 | 0.95 (0.50 to 1.81) | n/e | 53 | 2.08 (1.22 to 3.55) | 2.5 | – | – | – |
| Certolizumab (RAPID-axSpA22) | 24 | NA | NA | NA | 96 | 2.72 (1.59 to 4.65) | 2.3 | – | – | – |
| ASAS40 | ||||||||||
| Etanercept (EMBARK25) | 12 | 25 | 6.25 (0.33 to 118.2) | 5.5 | – | – | – | 76 | 2.09 (1.04 to 4.18) | 4.1 |
| Adalimumab (ABILITY-127) | 12 | 42 | 1.14 (0.35 to 3.65) | 33.3 | 142 | 2.96 (1.56 to 5.63) | 3.7 | – | – | – |
| Golimumab (GO-AHEAD28) | – | – | – | – | – | – | – | – | – | – |
| Certolizumab (RAPID-axSpA22) | 24 | NA | NA | NA | 96 | 4.09 (1.94 to 8.40) | 2.7 | – | – | – |
ASAS, Assessment in SpondyloArthritis international Society; CRP, C reactive protein; NA, not applicable; n/e, not possible to estimate; NNT, number needed to treat; nr-axSpA, non-radiographic axial spondyloarthritis; RR, risk ratio.